---
title: "Kamada Ltd. (KMDA.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KMDA.US.md"
symbol: "KMDA.US"
name: "Kamada Ltd."
industry: "Biotechnology"
datetime: "2026-06-13T21:00:00.696Z"
locales:
  - [en](https://longbridge.com/en/quote/KMDA.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KMDA.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KMDA.US.md)
---

# Kamada Ltd. (KMDA.US)

## Company Overview

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.kamada.com](https://www.kamada.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-13T04:30:13.000Z

**Overall: B (0.39)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 41 / 390 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 8.64% |  |
| Net Profit YoY | 26.80% |  |
| P/B Ratio | 1.65 |  |
| Dividend Ratio | 3.36% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 429184256.64 |  |
| Revenue | 181682000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 7.97% | B |
| Profit Margin | 11.21% | B |
| Gross Margin | 42.25% | B |
| Revenue YoY | 8.64% | B |
| Net Profit YoY | 26.80% | B |
| Total Assets YoY | 2.11% | C |
| Net Assets YoY | 2.95% | C |
| Cash Flow Margin | 126.25% | B |
| OCF YoY | 8.64% | B |
| Turnover | 0.48 | C |
| Gearing Ratio | 32.28% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Kamada Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "8.64%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "26.80%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.65",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.36%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "429184256.64",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "181682000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "7.97%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "11.21%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "42.25%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "8.64%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "26.80%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.11%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "2.95%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "126.25%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "8.64%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "32.28%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 21.07 | 38/390 | 25.10 | 22.45 | 20.51 |
| PB | 1.65 | 166/390 | 1.80 | 1.69 | 1.54 |
| PS (TTM) | 2.36 | 55/390 | 2.70 | 2.49 | 2.34 |
| Dividend Yield | 3.36% | 3/390 | 3.02% | 2.84% | 2.53% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | A | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-27T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 7.44 |
| Highest Target | 15.00 |
| Lowest Target | 11.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KMDA.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KMDA.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KMDA.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KMDA.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**